Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Pfizer’s CEO reflects on a year of discovery and what he thinks critics get wrong about vaccine pricing Albert Bourla talks about his employees' effort to develop a COVID-19 vaccine in record ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Pfizer will halt its development of a weight-loss drug that was being closely watched by investors, in a significant blow to the US pharmaceutical group. The company said on Monday that it would stop ...

Pfizer Chief Executive Albert Bourla says recent Seagen acquisition provides "tremendous opportunity for growth." This interview was recorded on Jan. 15, 2024, at the World Economic Forum meeting ...

Pfizer’s CEO Ian Read is to step down after eight years and will be replaced on 1st January by chief operating officer Albert Bourla. In contrast to Merck & Co. which has rescinded a company ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The meeting also involved the leaders of several American businesses, including FedEx Corp. CEO Raj Subramaniam, Boeing Co.’s senior vice president Brendan Nelson, Qualcomm’s CEO Cristiano Amon and ...

Albert Bourla provides an update on the effectiveness of current vaccines against the Omicron variant, the debate over mandates and how new antiviral drugs will change the way we live with Covid ...